Pharmacokinetics of Single Oral Doses of Apricitabine, a Novel Deoxycytidine Analogue Reverse Transcriptase Inhibitor, in Healthy Volunteers

By Holdich Tom  

Clinical Drug Investigation, Vol. 26, Iss. 5, 2006-01 ,pp. : 279-286

Adis International

Access to resources Recommend Favorite

Multiple-Dose Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with HIV-1 Infection

By Cahn Pedro  

Clinical Drug Investigation, Vol. 28, Iss. 2, 2008-01 ,pp. : 129-138

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor

By Moore K.H.P.   Cass L.M.   Dallow N.   Hardman T.C.   Jones A.   Boyce M.   Prince W.T.  

European Journal of Clinical Pharmacology, Vol. 56, Iss. 11, 2001-01 ,pp. : 805-811

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors

By Smith P.F.  

Clinical Pharmacokinetics, Vol. 40, Iss. 12, 2001-01 ,pp. : 893-905

Adis International

Access to resources Recommend Favorite

Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863

By  

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 2, 2014-03 ,pp. : 109-117

John Wiley & Sons Inc

Access to resources Recommend Favorite